CompletedNCT00971334

Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

Studying Down syndrome

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sequenom, Inc.
Principal Investigator: Allan T Bombard, MD
Sequenom, Inc.
Enrollment: 2502 enrolled
Eligibility: 18 years · FEMALE
Timeline: 2009 – 2011

Study locations (30)

University of South Alabama, Mobile, Alabama, United States
Grossmont Center for Clinical Research, La Mesa, California, United States
IGO, San Diego, California, United States
San Diego Perinatal Center, San Diego, California, United States
Women's Healthcare at Frost Street, San Diego, California, United States
Poway Womens Care, San Diego, California, United States
Visions Clinical Research, Boynton Beach, Florida, United States
University of Miami, Miami, Florida, United States
South Florida Perinatal Medicine, Miami, Florida, United States
Global Ob/Gyn Centers, Pembroke Pines, Florida, United States
Discovery Clinical Research, Sunrise, Florida, United States
Sheridan Clinical Research, Sunrise, Florida, United States
Fetal Diagnostic Institution of the Pacific, Honolulu, Hawaii, United States
Women's Clinic, Boise, Idaho, United States
Reproductive Genetics Institute, Chicago, Illinois, United States
+15 more locations on ClinicalTrials.gov

Collaborators

PRA Health Sciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00971334 on ClinicalTrials.gov

Other trials for Down syndrome

Additional recruiting or active studies for the same condition.

See all trials for Down syndrome →

← Back to all trials